Neuralgia News and Research

RSS
Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.
Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan announces launch of Lidocaine Patch 5% in the U.S.

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Findings could lead to treatments for chronic pain caused by nerve damage

Findings could lead to treatments for chronic pain caused by nerve damage

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Brainlab launches automated stereotactic radiosurgery planning tools at ESTRO 2015

Brainlab launches automated stereotactic radiosurgery planning tools at ESTRO 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.